Hiprex 1g Class 4 Defect: Braille Error, No Recall
Summary
Doncaster Pharma Limited has reported a Class 4 defect affecting five batches of parallel-imported Hiprex 1g tablets (PLPI: 56830/0284). The Braille embossing on outer packaging incorrectly states the strength as 1mg, while the printed text on all packaging and the Patient Information Leaflet correctly state 1g. MHRA confirms affected products remain within specification with no quality issues and no recall is required. Healthcare professionals are advised to explain the error to patients who rely solely on Braille when reading medicine cartons.
“The impacted products remain within specification and there is no issue with product quality. As a result, the affected batches are not being recalled.”
About this source
GovPing monitors MHRA Guidance & Safety for new pharma & drug safety regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 56 changes logged to date.
What changed
Doncaster Pharma Limited has identified a Class 4 medicines defect in which the Braille embossing on outer packaging of Hiprex 1g tablets incorrectly states the strength as 1mg. The printed text on outer packaging, immediate packaging, and Patient Information Leaflet correctly state the strength as 1g. Products remain within specification and are not being recalled.
Healthcare professionals should be aware that patients who rely solely on Braille may require an explanation of this labeling error when dispensed. No dosing risk exists as the product is supplied in a single strength. Patients should continue taking their medication and report any adverse reactions via the MHRA Yellow Card scheme.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20
Doncaster Pharma Limited has informed the MHRA of an error related to the Braille embossing on the outer packaging of certain parallel imported batches of Hiprex 1 g tablets (POM).
From: Medicines and Healthcare products Regulatory Agency Published 22 April 2026 Message type: Medicines recall/notification Medical specialty: Dispensing GP practices and Pharmacy Issued: 22 April 2026
DMRC reference number
DMRC- 39194203
Marketing Authorisation Holder
Doncaster Pharma Limited
Medicine Details
Hiprex 1g tablets
PLPI: 56830/0284
Active ingredient: methenamine hippurate
SNOMED code: 44366111000001107
GTIN: N/A
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 251352/BA | 04/2028 | 100 tablets | 27/10/2025 |
| 251358/BA | 04/2028 | 100 tablets | 21/01/2026 |
| 252137/BA | 04/2028 | 100 tablets | 04/02/2026 |
| 252137/BB | 04/2028 | 100 tablets | 11/03/2026 |
| 251358/BB | 04/2028 | 100 tablets | 27/03/2026 |
Background
Doncaster Pharma Limited has informed the MHRA of an error related to the Braille embossing on the outer packaging of the above mentioned parallel imported batches of Hiprex 1 g tablets (POM). It was identified that the embossed Braille text on the outer packaging incorrectly states the strength as 1mg. The printed text on the outer packaging, immediate packaging and Patient Information Leaflet (PIL) correctly state the strength as 1g.
| Correct Braille | Incorrect Braille | |
|---|---|---|
| The correct Braille message should read: | The incorrect Braille message reads as: |
Advice for Healthcare Professionals:
The impacted products remain within specification and there is no issue with product quality. As a result, the affected batches are not being recalled.
Healthcare professionals should, if requested, explain the Braille errors to patients who rely solely on Braille when reading medicine cartons. As the products are supplied in a single strength, there is no risk of dosing errors arising from the Braille issue.
Advice for Patients:
No action is needed from patients, continue to take medication from these batches of tablets. The actions will be controlled by the healthcare professionals who prescribe or dispense the medication who will provide appropriate support at the time of dispensing, where required.
Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information:
For all medical information enquiries and information on this product, please email regulatory@doncasterpharma.co.uk or quality.enquiries@doncasterpharma.co.uk, or telephone 01302 365 000.
For stock control enquiries, please email commercial@doncasterpharma.co.uk, or telephone 01302 365 000.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document
Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20
Updates to this page
Published 22 April 2026
Mentioned entities
Parties
Related changes
Get daily alerts for MHRA Guidance & Safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Guidance & Safety publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.